logo-loader
viewErgomed PLC

Ergomed's PeproStat successfully completes Phase II clinical trial

Andrew Mackie, chief business officer for Ergomed  PLC (LON:ERGO), tells Proactive they've successfully completed the Phase II clinical trial of their PeproStat blood thickening agent.

Mackie adds the  coagulant met the primary endpoint over standard of care (SOC) in time to haemostasis – in other words it stopped the flow of blood quicker than current treatments – with “statistical significance” in all surgery types tested.

Quick facts: Ergomed PLC

Price: 430 GBX

AIM:ERGO
Market: AIM
Market Cap: £205.36 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics. The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat...

on 11/16/2016

2 min read